← back to search

Dorothee Gramatzki

University Hospital of Zurich ·
Area of research
Genetics · Pulmonary and Respiratory Medicine
Research interest
Research interests include Glioma Diagnosis and Treatment, Brain Metastases and Treatment, Radiomics and Machine Learning in Medical Imaging, and Epigenetics and DNA Methylation.
h-index
26
citations
3,108
works
135
NIH funding
primary concept
email

Recent publications

The clinical and molecular landscape of diffuse hemispheric glioma, H3 G34-mutant
Neuro-Oncology 2025cited by 12position: middledoi
Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma
Acta Neuropathologica 2024cited by 45position: middledoi
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)
European Journal of Cancer 2023cited by 69position: middledoi
Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up
Journal of Neuro-Oncology 2023cited by 20position: middledoi
Anaplastic ganglioglioma—A diagnosis comprising several distinct tumour types
Neuropathology and Applied Neurobiology 2022cited by 22position: middledoi
Telomerase reverse transcriptase promoter mutation– and O6-methylguanine DNA methyltransferase promoter methylation–mediated sensitivity to temozolomide in isocitrate dehydrogenase–wild-type glioblastoma: is there a link?
European Journal of Cancer 2021cited by 16position: firstdoi
Chemotherapy for adult patients with spinal cord gliomas
Neuro-Oncology Practice 2021cited by 5position: firstdoi
The molecular evolution of glioblastoma treated by gross total resection alone
Neuro-Oncology 2020cited by 3position: firstdoi
DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development
Acta Neuropathologica Communications 2019cited by 75position: middledoi
Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities
Acta Neuropathologica Communications 2019cited by 62position: middledoi
Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations
Acta Neuropathologica 2018cited by 279position: middledoi
DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment
Neuro-Oncology 2018cited by 112position: middledoi
Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in <i>EGFR</i> -Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors
Clinical Cancer Research 2017cited by 178position: middledoi
Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma
Neurology 2017cited by 82position: firstdoi
Clinical and molecular subgroups of ependymoma in adulthood: An analysis of the German Glioma Network.
Journal of Clinical Oncology 2017cited by 2position: firstdoi
Clinical and molecular features associated with long-term survival of elderly patients with glioblastoma.
Journal of Clinical Oncology 2017cited by 1position: middledoi
PATH-24. MOLECULAR SUBGROUPS OF ADULT EPENDYMAL TUMORS: AN ANALYSIS OF THE GERMAN GLIOMA NETWORK
Neuro-Oncology 2017cited by 0position: middledoi
Chemotherapy for intracranial ependymoma in adults
BMC Cancer 2016cited by 32position: firstdoi
Erratum to: Gliomatosis cerebri: no evidence for a separate brain tumor entity
Acta Neuropathologica 2016cited by 2position: middledoi
HG-68COMBINED ALTERATIONS IN MAPK PATHWAY GENES, CDKN2A/B AND ATRX CHARACTERIZE ANAPLASTIC PILOCYTIC ASTROCYTOMA
Neuro-Oncology 2016cited by 0position: middledoi
DRES-13. EXTENDED TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA: AN ANALYSIS OF THE GERMAN GLIOMA NETWORK
Neuro-Oncology 2016cited by 0position: firstdoi
MPTH-23. LONG-TERM SURVIVAL WITH GLIOBLASTOMA IN THE ELDERLY
Neuro-Oncology 2016cited by 0position: middledoi
Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups
Acta Neuropathologica 2015cited by 314position: middledoi
Gliomatosis cerebri: no evidence for a separate brain tumor entity
Acta Neuropathologica 2015cited by 94position: middledoi
The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway
Oncogene 2015cited by 59position: middledoi
Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling
International Journal of Cancer 2014cited by 147position: middledoi
NDRG1 prognosticates the natural course of disease in WHO grade II glioma
Journal of Neuro-Oncology 2014cited by 22position: middledoi
Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy
International Journal of Cancer 2013cited by 118position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Michael Weller · Center for Neurosciences18 papers (2013–2024)Guido Reifenberger · University of Toronto16 papers (2013–2024)Bettina Hentschel · Leipzig University14 papers (2013–2024)Manfred Westphal · Universität Hamburg14 papers (2013–2024)Gabriele Schackert · Else Kröner-Fresenius-Stiftung12 papers (2013–2021)Ulrich Herrlinger · Brain (Germany)12 papers (2015–2024)Torsten Pietsch · German Center for Neurodegenerative Diseases11 papers (2013–2024)Andreas von Deimling · Stiftung Schleswig-Holsteinische Landesmuseen11 papers (2013–2024)Jörg Felsberg · Düsseldorf University Hospital11 papers (2015–2024)Markus Loeffler · Leipzig University of Applied Sciences9 papers (2013–2021)Stefan M. Pfister · Université du Québec8 papers (2015–2019)Patrick Roth · University Hospital of Zurich6 papers (2015–2024)David Capper · German Cancer Research Center6 papers (2015–2018)Kerstin Kaulich · Düsseldorf University Hospital5 papers (2013–2020)Michael Sabel · Düsseldorf University Hospital5 papers (2016–2021)Wolfgang Wick · Heidelberger Institut für Radioonkologie5 papers (2016–2021)David Jones · Mayo Clinic in Florida5 papers (2015–2019)J. C. Tonn · LMU Klinikum5 papers (2013–2024)Matthias Simon · Evangelisches Krankenhaus Bielefeld5 papers (2013–2017)Uwe Schlegel · Klinik Hirslanden4 papers (2016–2021)